Accelerated Hydrolysis of Aspirin Using Alternating Magnetic Fields
© to the authors 2009
Received: 28 March 2009
Accepted: 24 April 2009
Published: 7 May 2009
The major problem of current drug-based therapy is selectivity. As in other areas of science, a combined approach might improve the situation decisively. The idea is to use the pro-drug principle together with an alternating magnetic field as physical stimulus, which can be applied in a spatially and temporarily controlled manner. As a proof of principle, the neutral hydrolysis of aspirin in physiological phosphate buffer of pH 7.5 at 40 °C was chosen. The sensor and actuator system is a commercially available gold nanoparticle (NP) suspension which is approved for animal usage, stable in high concentrations and reproducibly available. Applying the alternating magnetic field of a conventional NMR magnet system accelerated the hydrolysis of aspirin in solution.
KeywordsGold nanoparticle Magnetic field Relaxation Hydrolysis Pro-drug
The biggest problem of drug-based therapy is selectivity because of side effects that can be dose-limiting. This challenge led to different strategies with chemically increased selectivity (pro-drug approach), and physically increased selectivity (physical stimuli such as lasers) .
The latter approach, hyperthermia, is used as sole agent or as an adjuvant therapy together with chemotherapy and radiotherapy , utilizing magnetic fields  and NIR lasers . Despite promising results, optical energy sources are mainly limited to the treatment of subcutaneous tumours. As in other areas of science, a combination of two effects might improve the situation decisively. The idea is to use the pro-drug principle together with an alternating magnetic field as physical stimulus, which can be applied spatially and temporarily controlled. Moreover, it is not limited to surfaces and delivers very small amounts of energy to the target, thereby avoiding thermal damage in non-treated areas.
As standard pulse program, the water suppression Watergate W5 pulse sequence with gradients using double echo was taken . It was modified for stimulating the hydrolysis of aspirin with a loop 1,000 times over a z-gradient of 100 μs length, of rectangular shape, 10% of maximum power, and alternating in both directions with a delay of 50 μs between each gradient. This sequence was looped 10 times with a delay of 100 ms in between, after which the standard pulse sequence started. A total of 512 scans were accumulated which resulted in a total experimental time of 45 min and 16 s (relaxation delay set to 0.7 s). After this modified pulse sequence, the standard pulse program with 16 scan was used to record the spectra for the analysis of the hydrolysis. Temperature measurements before and after applying the alternating gradient using an internal calibration system  resulted in a difference of 0.9 K for a sample without gold nanoparticle (NP), and 0.7 K for a sample with gold NP. Thus, the bulk temperature was kept constant. Measurements of pH were conducted before and after applying the alternating gradient. The pH remained constant (difference below 0.05). Furthermore, in the neutral pH range applied, the hydrolysis of aspirin is hardly affected from small pH variations . The spinning rate was 20 Hz in all measurements.
Results and Discussion
In the following, an explanation of the effect of stimulating the hydrolysis of aspirin is given. The gold NP used in this study with a gold core diameter of 1.9 nm and a small size distribution are covered by sulphur-bonded carboxylic acids to stabilize the NP. Recent results showed that gold NP, especially those stabilized by sulphur ligands, possess a magnetic moment . This type of magnetism might be classified as superparamagnetism . It can be rationalized by the formation of electron holes in the 5d-orbitals due to the gold–sulphur bond. The occurrence of these partially filled d-orbitals then gives rise to a magnetic moment similarly to the well known 3d-type ferromagnetics such as iron. Experimental data showed magnetic moments per Au atom attached to a sulphur-ligand from 0.006  to 0.0093 μB.
The magnetic moment of gold NP depends highly on the geometry and bonding, and since only recently the structure of a gold NP with sulphur ligands could be analyzed , reliable predictions about magnetic properties can at present hardly be made. Assuming that the gold NP of this study exhibit a similar magnetic behaviour, the ratio of 0.6 between surface atoms and total atoms would lead to a magnetic moment of 0.004 μB averaged over all atoms of such a gold NP (roughly 150 gold atoms). This would amount to a magnetic moment of 0.6 μB for the whole gold NP which is comparable to the magnetic moment of a ferromagnetic iron atom (2.2 μB).
Heating via hysteresis: Ferromagnetic NP of sizes above 100 nm show hysteretic behaviour but particles smaller than 10 nm are single-domain structured, do not show hysteresis, but transfer energy by relaxation processes .
Heating via inductive coupling: This mechanism was proposed by Hamad-Schifferli et al.  but in the case of gold NP cannot explain the energy coupling. Consequently, this explanation has not been given again by this group in further work.
Heating via relaxation: The dominant relaxation process depends on the anisotropy energy, the volume of the particle, viscosity of the solution and temperature. The very high anisotropy energy values of 109 J/m3 measured for gold NP  would favour Brown relaxation where the whole particle changes its orientation . However, the small size (gold core diameter of 1.9 nm plus stabilizing ligand shell for the AurovistTM gold NP) would favour Néel relaxation  with a changing magnetic moment responsible for the energy conversion from magnetic to thermal .
In the liquid suspension, energy can also be transferred via frictional losses due to the magnetic torque produced by the alternating magnetic field and the remanent magnetization . Without further information, it is impossible to specify which mechanism and/or mixture of mechanisms is operating. Assuming the Brown relaxation mechanism ferromagnetic (within this size regime: superparamagnetic) iron oxides produced thermal powers of ca. 100 W per gram . In these cases a strong increase of temperature is obtained which was not observed in the present approach with gold NP. The relaxational power loss equation contains the squared magnetic moment of the particles . Assuming a 100 fold reduced magnetic moment of the gold NP compared to an iron oxide NP, this would lead to a 104 fold reduction of the power deposited (10 mW per gram). With this little amount of energy, only a small fraction of the solution can represent an activated/heated volume for the hydrolysis. Essentially, assuming Brown relaxation the rotational energy of the whole particle is transformed into rotational, vibrational and translational energy  of the surrounding nanoscopic layer of bulk solvent and aspirin molecules, thereby increasing the hydrolysis rate. This reasonable assumption can explain the overall increase in the hydrolysis rate without simultaneous bulk heating. However, typical hyperthermia conditions could probably also be used to hydrolyse pro-drugs as exemplified in this study.
The application of time and spatially resolved magnetic fields was successfully used to accelerate a typical activating reaction used for pro-drugs. Furthermore, the combined approach allows (i) full chemical flexibility in pro-drug design exploiting the vast chemical and medicinal experience in this field, (ii) application of the rich gold chemistry [20, 21] (iii) the direct observation by NMR, (iv) full control of the process with conventional NMR systems and (v) small amounts of deposited energy minimizing thermal side reactions. Pro-drugs already in use can now be tested with an appropriate nanoparticle-magnet system in conventional MRI instruments.
I thank C. Griesinger and S. Becker from the Max-Planck-Institute for biophysical chemistry (Göttingen, Germany) and M. Keusgen from the Department of Pharmaceutical Chemistry (Marburg, Germany) for helpful discussions during the course of this work. This work was supported by Max-Planck-Society.
- Stehr J, Hrelescu C, Sperling RA, Raschke G, Wunderlich M, Nichtl A, Heindl D, Kürzinger K, Parak WJ, Klar TA, Feldmann J: Nano Lett.. 2008, 8: 619. ; COI number [1:CAS:528:DC%2BD1cXhtFSgsr0%3D]; Bibcode number [2008NanoL...8..619S] 10.1021/nl073028iView Article
- Westermann AM, Jones EL, Schem B-C, van der Stehen-Banasik EM, Koper P, Mella O, Uitterhoeve ALJ, de Wit R, van der Velden J, Burger C, van der Wilt CL, Dahl O, Prosnitz LR, van der Zee J: Cancer. 2005, 104: 763. COI number [1:CAS:528:DC%2BD2MXhtVSltrzI] 10.1002/cncr.21128View Article
- Ito A, Shinkai M, Honda H, Kobayashi T: J. Biosci. Bioeng.. 2005, 100: 1. COI number [1:CAS:528:DC%2BD2MXhtVaqu7vM] 10.1263/jbb.100.1View Article
- Huang X, El-Sayed IH, Qian W, El-Sayed MA: J. Am. Chem. Soc.. 2006, 128: 2115. COI number [1:CAS:528:DC%2BD28XntFCltQ%3D%3D] 10.1021/ja057254aView Article
- Liu M, Mao X, He C, Huang H, Nicholson JK, Lindon JC: J. Magn. Reson.. 1998, 132: 125. ; COI number [1:CAS:528:DyaK1cXjsFSjsbg%3D]; Bibcode number [1998JMagR.132..125L] 10.1006/jmre.1998.1405View Article
- Farrant RD, Lindon JC, Nicholson JK: NMR Biomed.. 1994, 7: 243. COI number [1:STN:280:DyaK2M7ltFGhsQ%3D%3D] 10.1002/nbm.1940070508View Article
- Kelly CA: J. Pharm. Sci.. 1970, 59: 1053. COI number [1:CAS:528:DyaE3cXkvVSns7w%3D] 10.1002/jps.2600590802View Article
- Garitaonandia JS, Insausti M, Goikolea E, Suzuki M, Cashion JD, Kawamura N, Ohsawa H, de Muro IG, Suzuki K, Plazaola F, Rojo T: Nano Lett.. 2008, 8: 661. ; COI number [1:CAS:528:DC%2BD1cXptl2jsg%3D%3D]; Bibcode number [2008NanoL...8..661G] 10.1021/nl073129gView Article
- Leslie-Pelecky DL, Rieke RD: Chem. Mater.. 1996, 8: 1770. COI number [1:CAS:528:DyaK28XksFahs7o%3D] 10.1021/cm960077fView Article
- Dutta P, Pal S, Seehra MS, Anand M, Roberts CB: Appl. Phys. Lett.. 2007, 90: 213102. Bibcode number [2007ApPhL..90u3102D] Bibcode number [2007ApPhL..90u3102D] 10.1063/1.2740577View Article
- Negishi Y, Tsunoyama H, Suzuki M, Kawamura N, Matsushita MM, Maruyama K, Sugawara T, Yokoyama T, Tsukuda T: J. Am. Chem. Soc.. 2006, 128: 12034. COI number [1:CAS:528:DC%2BD28XosFarsbw%3D] 10.1021/ja062815zView Article
- Jadzinsky PD, Calero G, Ackerson CJ, Bushnell DA, Kornberg RD: Science. 2007, 318: 430. ; COI number [1:CAS:528:DC%2BD2sXhtFOjtb%2FP]; Bibcode number [2007Sci...318..430J] 10.1126/science.1148624View Article
- Hergt R, Dutz S, Müller R, Zeisberger M: J. Phys. Condens. Matter. 2006, 18: S2919. ; COI number [1:CAS:528:DC%2BD28XhtFelsr%2FE]; Bibcode number [2006JPCM...18S2919H] 10.1088/0953-8984/18/38/S26View Article
- Hamad-Schifferli K, Schwartz JJ, Santos AT, Zhang S, Jacobson JM: Nature. 2002, 415: 152. Bibcode number [2002Natur.415..152H] Bibcode number [2002Natur.415..152H] 10.1038/415152aView Article
- Hernando A, Crespo P, García MA, Pinel EF, de la Venta J, Fernández A, Penadés S: Phys. Rev. B. 2006, 74: 052403. Bibcode number [2006PhRvB..74e2403H] Bibcode number [2006PhRvB..74e2403H] 10.1103/PhysRevB.74.052403View Article
- Brown WF: Phys. Rev.. 1963, 130: 1677. Bibcode number [1963PhRv..130.1677B] Bibcode number [1963PhRv..130.1677B] 10.1103/PhysRev.130.1677View Article
- Néel L: Adv. Phys.. 1955, 4: 191. Bibcode number [1955AdPhy...4..191N] Bibcode number [1955AdPhy...4..191N] 10.1080/00018735500101204View Article
- Hergt R, Dutz S: J. Magn. Magn. Mater.. 2007, 311: 187. ; COI number [1:CAS:528:DC%2BD2sXjtVeisbY%3D]; Bibcode number [2007JMMM..311..187H] 10.1016/j.jmmm.2006.10.1156View Article
- Flygare WH: Acc. Chem. Res.. 1968, 1: 121. COI number [1:CAS:528:DyaF1cXhtFOitbg%3D] 10.1021/ar50004a004View Article
- Schmid G: Chem. Soc. Rev.. 2008, 37: 1909. ; COI number [1:CAS:528:DC%2BD1cXhtVOitbrN]; Bibcode number [2008unph.book.....S] 10.1039/b713631pView Article
- Daniel M-C, Astruc D: Chem. Rev.. 2004, 104: 293. COI number [1:CAS:528:DC%2BD3sXpvFGlur0%3D] 10.1021/cr030698+View Article